Dr Krina Patel discusses updated results, presented at ASH 2025, from the phase II iMMagine-1 trial evaluating anitocabtagene autoleucel (anito-cel), an anti-BCMA CAR T-cell therapy, in heavily pre-treated relapsed/refractory multiple myeloma.

She highlights high overall and complete response rates, rapid MRD negativity, encouraging progression-free survival, and a manageable safety profile with low rates of severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome (ICANS), and no delayed neurotoxicity observed to date.